



Physiological Renormalization of Skin in Traumatic, Irradiation, Autoimmune, and Aging Conditions Using S2RM Stem Cell Released Molecules Enhances Healing and Reduces Pain

Journal:	<i>Journal of Dermatological Treatment</i>
Manuscript ID	2019-JDT-OR-0148
Manuscript Type:	Original Article
Date Submitted by the Author:	28-Mar-2019
Complete List of Authors:	Maguire, Greg; NeoGenesis Inc, R&D McGee, Steven; NeoGenesis Inc, R&D Paler, Lee; NeoGenesis Inc, R&D Green, Linda; NeoGenesis Inc, R&D Brown, Holly; Looking and Feeling FAB O'Brien, GERALYN; Integrative Cancer Review Lacina, Tracy; Skin Deep Salon & Spa Glazer, Donna; Faceit London Isacescu, Valentin; North County Clinical Research
Keywords:	Stem cells, Fibroblasts, Skin Disease, Aged Skin

SCHOLARONE™
Manuscripts

Physiological Renormalization of Skin in Traumatic, Irradiation, Autoimmune, and Aging Conditions Using S2RM Stem Cell Released Molecules Enhances Healing and Reduces Pain

Greg Maguire^{1@}, Ph.D., Steven McGee¹, Lee Paler¹, Linda Green¹, Holly Brown², Geralyn O'Brien³, Tracy Lacina⁴, Donna Glazer,⁵ Valentin Isecescu, M.D.⁶

1. NeoGenesis Inc, San Diego, CA 92121 USA; 2. Looking and Feeling FAB, Inc, 3. Integrative Cancer Review, 4. Skin Deep Salon & Spa, 5. Faceit London, London UK, 6. North County Clinical Research, Oceanside, CA 92056 USA

@ Corresponding author

Abstract

Wounds, aging, and autoimmune conditions of the skin involve a disruption of skin homeostasis, especially a disruption of proteostasis. In this study we used S2RM technology, a proprietary combination of stem cell released molecules from multiple types of skin stem cells, to renormalize homeostasis of the skin, including a renormalization of proteostasis. Dramatic reductions in scarring, pain, redness, and inflammation, more rapid and complete wound healing, and an overall enhancement of the appearance of the skin were achieved in a number of skin conditions. Prevention of radiation dermatitis was achieved by concurrent topical administration of S2RM during radiation treatment. The current study demonstrates that simple topical application of S2RM technology is a powerful means to renormalize homeostasis of the skin, and remediate and prevent a number of skin indications.

Introduction

Multiple types of stem and progenitor cells are resident in the skin to maintain the skin's physiology and structure (Fuchs and Green, 1978; Mascré et al, 2012). Recently the importance of proteostasis in the skin (Skirou et al, 2017) and the molecules, such as PDGF, that stem cells release in healing tissue has been recognized (Maguire, 2013), particularly in the skin (Rivera-Gonzalez et al, 2016) for the development of therapeutics that mimic and facilitate protein circuits for wound healing (Maguire, 2018). In 1975, Howard Green at MIT showed for the first time that identified cells, what he called

human keratinocytes, and what we now define as stem cells, could be passaged clonally for hundreds of generations without losing their diploidy or their ability to make tissue (Rheinwald and Green, 1975). Later recognized was that stem cells could be passaged in the laboratory in such a manner as to collect the molecules that they release for means of therapeutic development (Maguire, 2016). In this way, the major therapeutic benefit of stem cells, acting through the many molecule types that they release (Maguire, 2013), could be applied directly to the patient without the vagaries associated with using the stem cells themselves (Maguire, 2016).

The conditioned medium containing growth factors, cytokines, and other molecules, secreted, not extracted, by stem cells has demonstrated efficacy in rescuing cells from a variety of stress factors (Maguire et al, 2019) enhancing hair growth (Fukuoka and Suga, 2015), alteration of matrix metalloproteinase (MMP) expression in dermal fibroblasts that have been exposed to ultraviolet radiation (Son et al, 2015); controlling collagen production, modulating endothelial cell, fibroblast, and keratinocyte migration (Hu et al, 2013), and improving scarless wound healing (Wang et al, 2017; Chicharo et al, 2018). These phenomena may have potential benefit in addressing aged skin conditions, cutaneous wound healing, photodamage and subsequent wrinkling and elastosis, and scarless wound healing. The choice of stem cell type is crucial for the development of a safe and efficacious secretome to be used in skin care products, such that skin derived stem cells should be used and not bone marrow stem cells (Maguire, 2019b).

Chronologically aged skin is thin, dry, and finely wrinkled, while photoaged skin typically appears leathery, lax, with coarse wrinkles, “broken”-appearing blood vessels (telangiectasia), and uneven pigmentation with brown spots (lentigines) and yellowish color due to advanced glycation end products (Corstjens et al, 2008). Histologically, both aged and photoaged skin display epidermal differences compared to normal skin. Effects of natural aging and photoaging on the dermis are also profound and involve deleterious alterations to the collagenous extracellular matrix. Evidence indicates that accumulation of fragmented dermal extracellular matrix (ECM) is a key factor that

mediates many of the characteristic features of aged human skin (Rittie and Fisher, 2015).

In aging skin, facial rhytides are common and are of concern to many patients seen at dermatology clinics. The cause of facial wrinkles is multifactorial involving accumulated photodamage, muscular hyperactivity, age-related volume loss, and diminution of stem cell function in aged skin. Complex II activity within mitochondria is significantly decreased with age in fibroblasts, but not in keratinocytes (Bowman and Birch-Machin, 2016). Complex II in mitochondria are a powerful regulator of reactive oxygen species (ROS) and have a two-fold greater activity in skin compared to liver (Anderson et al, 2014). Ultraviolet radiation causes increased oxidative stress leading to DNA damage, tissue damage, and the accumulation of reactive oxygen species, resulting in reduced procollagen synthesis in human skin fibroblasts (Quan et al, 2004). Damage to skin connective tissues derived from fibroblasts is responsible for the characteristic aged appearance of photodamaged skin (Smith et al, 1962).

Wound repair is an elaborate and continuous process that can be thought of, in an oversimplified manner, as three overlapping phases, the inflammatory, proliferative, and remodeling phases. Age-related changes in wound repair have been described in each of these phases (Gerstein et al. 1993; Gosain and DiPietro 2004). Reduced expression of the epidermal stem cell markers melanoma chondroitin sulfate proteoglycan and integrin $\beta 1$ has been observed in human skin, while some stem cell numbers remained constant, suggestive of disruption of proteostasis in aged skin and not a simple diminution of skin cell numbers (Giangreco et al. 2008). Thus targeting the disruption of proteostasis with a proteostatic renormalization strategy may be warranted.

Our studies here showed that the stem cell released molecules (S2RM) from multiple types of stem cells derived from human skin, used as a means to renormalize proteostasis of the skin, were well tolerated in human subjects as demonstrated by a Human Insult Repeat Patch Test (HIRPT), and proved highly efficacious in treating or preventing a number of skin conditions, including aged skin, dermatitis, including radiation dermatitis, trauma, acne, and autoimmune related issues.

Methods

Stem Cell released Molecules

A proprietary collection of stem cell lines derived from human skin were cultured using no penicillin/streptomycin under hypoxic conditions. When cultures reached confluence, they were passaged for a limited number of times before disuse. Total conditioned medium from the multiple cell types, containing a soluble fraction and an exosome fraction, was harvested at each passage and the passages combined into one batch for product development. Parts of our stem cell technology used here are covered by US patents: 9545370; 9446075; 20140205563; 20130302273.

Case Studies

In all cases an open label application of NeoGenesis Recovery was used to treat the skin condition. Simple topical administration to the affected area without other products or procedures was utilized.

Safety Studies, HRIPT

We used the Human Repeat Insult Patch Test (McNamee et al, 2008) to assess primary and accumulative irritation, and/or allergic contact sensitization, in human subjects, male and female, between the ages of 18 and 66. All subjects were free of skin disease, and were prohibited from using topical or systemic antihistamines and steroids beginning seven days prior to the onset and throughout the duration of the study. Measurements were performed by a trained rater technician. For the induction phase of the study, the patches of 0.1 g of S2RM per 1X1 inch square Webril dressing, were applied 3 times weekly for 3 weeks for a total of 9 applications. The patches were removed 48 hours after application and evaluated before the a fresh patch was reapplied to the same area. For the challenge phase of the study, two weeks after the final induction phase patch was applied, an adjacent, virgin area of skin then received a fresh patch and was evaluated at 24 and 72 hours following application of the patch. Ratings were scored using the following table:

0 – No visible skin reaction

- + - Barely perceptible or spotty erythema
- 1- Mild erythema covering most of the test site
- 2- Moderate erythema, possible mild edema
- 3- Marked erythema, possible edema
- 4- Severe erythema, possible edema, vesiculation, bullae, and/or ulceration

Results

Batch Reproducibility – Total protein

The method of Bradford was used in all protein determinations (Ernst and Zor, 2010). The Bradford protein assay is a spectroscopic analytical procedure used to measure the concentration of protein in a solution. Samples, performed in duplicate, from a total of 15 batches of S2RM were analyzed. The variation between duplicates in all cases was less than 10%. Five samples of different S²RM batches, and 5 samples of the individual batches of SRM from the individual cell lines that make-up the S²RM, were analyzed for total protein. All samples were taken from frozen aliquots of batches previously used to make skin care products with demonstrated efficacy. All batches produced at least 500 ug/ml of total protein, with a high value in one batch of 630 ug/ml. The mean value of all batches was 554 ug/ml. The variability in all the batches was 20% or less. With the exception of one batch displaying a high protein count (630ug/ml), the rest of the batches had a variability of 12% or less.

Skin Safety Testing, Irritation

Ninety-one (91) qualified subjects, male and female, ranging in age from 18 to 66 years, were selected for this evaluation. Fifty (50) subjects completed the study. The remaining subjects discontinued their participation for various reasons, none of which were related to the application of the test material. Of the 50 subjects completing the study, all were rated at 0 during both the induction phase and the challenge phase, indicating that the S2RM induced no immediate or long term irritation, or allergic reaction.

Skin Testing Efficacy, Case Studies

We used topical application of the stem cell based S2RM technology to treat a number of skin conditions involving trauma, autoimmunity, and aging. All procedures used an open label topical application of NeoGenesis Recovery, containing 70% of the S2RM material.

1. Traumatic Wounds

For analysis of traumatic wounds, we treated patients with scalpel surgery or wounds from traumatic accidents. In Figure 1 a patient had a tumor about the size of a ping pong ball (about 40mm in diameter) removed from her leg, leaving a large void and a very large incision. The patient was upset by the appearance of the wound, and her physician recommended using NeoGenesis' Recovery to aid the closure and for anti-scarring benefit. One year post-surgery there was complete healing, normal remodeling of the tissue and extracellular matrix, with no scarring.



Figure 1. Before and after surgery using S2RM technology. After photo was one year following surgery.

In another subject (Fig.2) who had experienced traumatic wounds to his head, legs, torso, arms and hands due to a bicycle accident, the patient used Recovery for more complete and faster healing. As a competitive bicycle racer, he had been in previous

like accidents, and compared his healing using Recovery to past experiences. He also suggested himself to compare the healing effects of Recovery versus no treatment by using Recovery on one hand, but not the other. Both arms and hands were lacerated and bleeding to a similar degree. Twice daily application of Recovery to the arm was compared to the left hand control. An obvious faster and more complete wound healing was observed using Recovery on the arm (Fig. 2 A and B) compared to not using Recovery on the hand (Fig. 2 C and D).



Figure 2. Traumatic wounds to the arms and hands were more completely and faster healing using twice daily Recovery (S2RM) application. A. Initial traumatic wound to arm. B. After 21 days following initial traumatic wound, using Recovery (S2RM)

application twice daily. C. In the same patient, in the same traumatic event, wounds were compared without the use of Recovery (S2RM) to those shown in A and B where Recovery (S2RM) was used. Here showing the initial traumatic wound. D. Wound recovery 21 days following the initial traumatic wound were followed without the application of Recovery (S2RM). Wound healing with the use of Recovery (S2RM) shown in A and B was faster and more complete than that without the use of Recovery (S2RM) as shown in C and D.

2. Radiation Treatment and Chemical Peel

Prior to radiation treatment, a plastic surgeon removed the scar tissue from the patient's breast that had resulted from a lumpectomy. Unfortunately, the patient simultaneously opted to include an elective procedure of a laser and chemical peel, resulting in severe blistering and burning (Figure 3A). About 3 weeks later the patient began radiation treatment for cancer. Recovery was used twice daily and no peeling, blistering, or scarring was observed. Her skin darkened for about 10 days, and then dissipated. The results were especially surprising to the attending physician and nurses given the patient also suffers from Lupus, making her very sensitive to these treatments.



Figure 3. Before and after chemical peel and radiation treatment. Chemical peel burn is shown in A. After photo (B) is 9th day of radiation treatment, and C. last day of treatment 21 days after initial treatment. S2RM technology topically applied twice daily.

3. Post LASER Recovery

LASER treatment for chronologically aged skin and scarring is common. Fractional ablative lasers create zones of ablation at variable depths in the layers of skin with subsequent induction of collagen production, wound healing, and collagen remodeling.

Recent studies suggest that the ablative zones in the skin may also be used in the immediate postoperative period to enhance delivery of drugs and other substances such as platelet-rich plasma or stem cell released molecules (Waibel et al, 2013). We therefore used the NeoGenesis stem cell released molecule-based product during the immediate postoperative period as a twice daily topically applied procedure. The inflammation, pain, and redness were dramatically reduced in three patients using the Recovery product. Those practitioners administering the procedure also observed an increased efficacy with coadministration of the S2RM product.



Figure 4. Post Laser treatment using NeoGenesis Recovery. Patient is shown just after the procedure on the left, and 5 days postprocedure on the right.

4. Atopic Dermatitis (Eczema)

Atopic eczema, also known as atopic dermatitis and commonly referred to as eczema, is a long-term relapsing skin condition that causes both physical and psychological suffering and can have a detrimental impact on quality of life for individuals and their family. The disease is one of the 50 most burdensome globally (Weideinger and Novak, 2016). The mainstay treatments include regular and consistent application of topical medication, predominantly emollients and steroid preparations (Santer et al, 2012). Treatment failure is common leading to wastage of the prescriptions (Smith et al, 2010b). We presented the subject with an easy to use topically applied product applied twice daily. One patient presented in Figure 4 had suffered with the rash as shown for over twenty years. Within 30 days of the treatment with the S2RM product, the rash and pruritis had significantly reduced in severity.



Figure 4. Treatment of eczema with topical application of S2RM technology applied daily for two months. Patient has suffered with this rash for over 20 years.

5. LASER treatment with postoperative Recovery versus standard of care.

To test whether our S2RM-based product would provide superior postoperative care to LASER patients compared with the standard of care, we applied Recovery on one hand and the standard of care on the other hand of one patient who had both hands treated equally with LASER. The photos demonstrate a reduction in redness of the Recovery treated hand compared to the control hand treated with the standard of care. The patient also reported a significant reduction in pain using Recovery compared to the control.



Figure 5. Within subjects comparison of recovery from laser treatment with topical standard of care versus S2RM stem cell released molecules topical care. The subject was irradiated with a XYZ laser on both hands. The top photo shows recovery from the laser wound using the standard of care, XYY cream. The lower photo shows recovery from the laser procedure using S2RM stem cell technology.

6. Psoriasis

Psoriasis is a chronic autoimmune condition affecting approximately 2% of the population (Kurd and Gelfand, 2012). While the cause of psoriasis is unknown, hyper-reactivity of Th1, Th17, dysregulation of Treg, and the complex relationships between immune system cells and keratinocytes and vascular endothelium play a significant role (Deng et al, 2016). Thus in psoriasis, hyperactivity of Th1 and Th17 means that T cells are activated against viral and bacterial infection, activating macrophages, and dysregulation of Treg means that the activation of Th1 and Th17 may be misguided and uncontrolled (for a short review see Taylor, 2017). Evidence also shows that plasmacytoid dendritic cells (pDC) may be central to disease development (Wohn et al, 2013). The pDCs produce about 1000 times more type I interferon (IFN-I) than any other cell type (Nestle et al, 2005), and account for about 50% of all circulating IFN-I following infection (Swiecki and Colonna, 2010). Nestle et al (2005) have proposed that pDCs in hereditary predisposed individuals subject to certain environmental conditions acting through the secretion of IFN-I, induce autoimmune T cells that elicit a psoriasiform phenotype (Nestle et al, 2005). Currently there is no fully satisfactory therapy against psoriasis and patients frequently report dissatisfaction with the treatment (Belinchón et al, 2016). A number of studies suggest that stem cell therapy may be useful in the treatment of psoriasis (Owczarczyk-Saczonek et al, 2017). Because the efficacy of stem cell therapy is often ascribed to the molecules and exosomes released by the stem cells (Maguire, 2013; Maguire, 2016), we used topical S2RM technology to treat the psoriasis.

Using a twice daily topical application of Recovery, the subject began to see a reduction in redness and pruritis within one week. By day 42 as shown in Figure 6, the patient had a near eradication of the psoriasis that was presenting on his arms and elbows.



Figure 6. Before and after (Day 42) using Recovery on a patient with psoriasis.

7. Recovery From Radiation Treatment for Cancer

Skin color changes are key biomarker for the ill effects of irradiation on the skin during breast cancer treatment, and darkening of the skin correlates in a linear manner with the maximal dosage of irradiation (Yamazaki et al, 2018). Irradiated skin shows a number of changes, including damage of the dermal stem cells and fibroblasts (Hur and Yoon, 2017). Miller et al (2012) have shown the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in 176 patients undergoing breast or chest wall radiotherapy. Results showed no difference between treatment and placebo when the mean maximum grade of radiation dermatitis was used as primary endpoint, but did show a reduction in the mean grade of discomfort or burning. Because of the ability of the S2RM technology to quell inflammation and pain, and to rebuild tissue, we used a topical application of Recovery twice daily to treat radiation dermatitis. Figure 7 shows one such patient treated following the completed radiation therapy protocol. A total of 33 treatments of proton radiation were received between Aug 2017 and Sept 2017. She underwent two lumpectomies followed by a mastectomy and four rounds of chemotherapy. Within two days of topically applying Recovery, the patient began to feel a reduction in pain and sensitivity of the treated area.



Figure 7. Post proton radiation treatment in cancer patient. Photos from top left to bottom right are at day 1, 7, 14, and 27 post radiation treatment, and beginning of Recovery (S2RM) topical application.

8. Fluorouracil (5-FU) Treatment

Fluorouracil is commonly given systemically for anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers, as well as topically for some skin cancers. Frequent side effects include inflammation of the mouth, loss of appetite, low blood cell counts, hair loss, and inflammation of the skin. The patient in Figure 8 was prescribed topical fluorouracil for 30 days. Experiencing severe pruritis, pain, bleeding, and significant wounds on a large area of her face (Pictures on the left column), and having been recommended to use Vaseline by medical care team, she reached out to her esthetician for help with the itching and wounds. Recovery was applied twice daily, and as shown in the pictures on the right column, the severity of the wounds and the

bleeding was greatly mitigated in 24 hours. Her pruritis and pain were self reported to be “greatly reduced.”



Figure 8. Post Fluorouracil (5-FU) treatment in cancer patient. Left column is the patient before application of Recovery, and the pictures in the right column show the patient 24 hrs following the initial application of Recovery.

9. Prevention of Radiation Dermatitis Using Recovery During Radiation Treatment

Given that post radiation treatment with Recovery was highly effective in several patients, several new patients were presented to us before their radiation treatment began in the hope that the S2RM technology would prevent, or mitigate, the induction of radiation dermatitis. Although some physicians still recommend patients not apply

topical products before radiation treatment, topical application of products just before radiotherapy is safe and not contraindicated (Baumann et al, 2018). With concurrent administration of Recovery twice daily during radiation treatment the patient's skin did not darken or become red, indicating that the Recovery was preventing radiation dermatitis. Healing of the scar from scalpel surgery of the breast was also enhanced.




Figure 9. S2RM application during radiation treatment in cancer patients prevent radiation dermatitis and augments scarless healing of scalpel surgery. Patient had bilateral mastectomy; lymph/aux node dissection; thyroidectomy, and then treated with chemo followed by radiation treatment. The photos, from top left to bottom right, were captured at weeks 1,2,3,4,5,13.

10. Chemo Associated Rash

Cancer patients are often found in the hospice, and palliative care is critical to their well being. A number of drugs used in cancer treatment can cause skin problems, including

1
2
3 rashes. One drug example is EGFR (epidermal growth factor receptor) inhibitors. These
4 drugs are often prescribed for patients with colon, head and neck, pancreatic, non-small
5 cell lung, and breast cancers. A number of this class of drug are available, including
6 cetuximab (Erbix), panitumumab (Vectibix), erlotinib (Tarceva), gefitinib (Iressa), and
7 lapatinib (Tykerb/Tyverb). Although topical vitamin K3 was proposed to provide benefit
8 as a prophylactic for cetuximab-induced rash in patients with metastatic colorectal
9 cancer, a recent Phase II, placebo-controlled study of vitamin K3 cream did not support
10 any clinical or immunohistochemical benefit (Eriksen et al, 2017). Similarly, in a recent
11 Phase II, double-blind, vehicle controlled study, vitamin K1 cream as prophylaxis for
12 cetuximab-induced skin toxicity did not reduce the incidence of grade ≥ 2 skin rash
13 (Hofheinz et al, 2018).
14
15
16
17
18
19
20
21
22

23 One patient experiencing chemotherapy induced rash used NeoGenesis Recovery
24 serum applied topically twice a day to the affected areas. In one week, a self reported
25 significant improvement was achieved. The redness of the rash faded, the raised areas
26 diminished, the blisters went away, and the pruritis completely stopped. The patient
27 reported, "Recovery serum is a miracle product. I highly recommend it to anyone with
28 skin issues from chemo."
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 10. Patient underwent chemo for breast cancer. One side effect was a rash that worsened with each treatment, leading to scabbing and bleeding over a 3 month period. Recovery applied twice a day for seven days significantly improved the look and feel of the skin. It also reduced the pain and irritation for the patient. From the patient: "No other product has helped like Recovery." This patient was treated with a combination of Cyclophosphamide and Doxorubicin for four weeks.

11. Old Scar Remediation

We tested Recovery in one subject who had a one year old scar that had resulted from a Fraxel Laser resurfacing procedure. The appearance of the scar had remained stable for one year. After one year, topical application of Recovery twice daily resulted in a significant reduction in the scar as shown in Figure 11. This was not a thick scar with a raised surface area, rather appeared as an atrophic scar with red and dark hyperpigmentation.



Figure 11. Remediation of old scar that had resulted from Fraxel Laser treatment. Scar persisted as shown in the left photo for one year despite treatment from the patient's dermatologist. Within 30 days using twice daily application of Recovery the scar became nearly invisible.

12. Chronologically aged skin

We tested the effects of Recovery on the chronological aging of the skin in twenty subjects. Topical application of Recovery was done twice daily. We saw an average 67% reduction in the number of lines, with a range between 57% and 75% reduction. Measurements were made of the crow's feet lines surrounding the eyes. Although the rater visually observed a reduction in lines in other parts of the face, no quantification was performed in those areas.



Figure 12. Anti-aging effects of topically applied S2RM. Picture on the left is the subject before treatment, and the picture on the right is 34 days after beginning treatment with Recovery.

13. Acne

Pathogenesis of acne is characterized by androgen-stimulated overproduction of sebum, follicular hyperkeratinization, inflammatory mediators, and colonization by organisms such as *Propionibacterium acnes*. The etiology of acne is not well understood. While hereditary factors, including genetics may influence a patient's risk of developing acne, the prevalence of adult acne in the US is increasing over the last few decades, where significant hereditary changes, or germline genetic variants are unlikely. Rather, environmental conditions, including diet, likely underlie the multifactorial etiology of acne (Mahmood and Bowe, 2014) In the medical setting, the standard of care for inflammatory acne is often a combination therapy including a retinoid and benzoyl peroxide. For moderate-to-severe cases, an oral antibiotic is also often prescribed, usually for no more than 4 months. Given the inflammatory and

cellular perturbation in acneic skin, we used Recovery, a stem cell conditioned media product containing product topically applied to the affected area.

Recovery was tested on four acne patients with results typified in Figure 13. Using a topical application of Recovery twice daily, acne breakout was shown to diminish in all 4 subjects within two months.



Figure 13. Simple topical application of S2RM technology using NeoGenesis Recovery was administered twice daily. Within 7 weeks of treatment initiation, the acneic breakout as shown by redness, whiteheads, and blackheads was significantly reduced.

Discussion

Restoration of the skin's extracellular matrix (ECM), and considering only the structural and mechanical properties of the dermal extracellular matrix, is critical to dermal maintenance and repair. In vitro studies show that fibroblasts in a mechanically stiffer

environment produce more collagen and fewer MMPs than fibroblasts cultured in a more flexible collagen matrix (Mauch et al. 1988; Rittié et al. 1999; Eckes et al. 2006). Further, studies of human skin have shown that local increase in mechanical forces within the dermis can reprogram fibroblasts to up-regulate collagen production in vivo (Wang et al. 2007; Quan et al. 2013), of which the correlative effects can be observed clinically in human subjects through the addition of collagen to the dermis using dermal filler injections (Turlier et al, 2013). Although fibroblasts and mesenchymal stem cells are known to secrete procollagen and collagen (Goldberg and Sherr, 1973; Amable et al, 2014), whether the effects we observed in this study were partially due to the topical application of secreted pro collagen and collagen is unknown. In favor of this suggestion, fibroblasts have been shown to secrete exosomes that contain collagen (Hong et al, 2008). As lipophyllic structures that are known to deliver signals in the keratinocyte layer (Lo Cicero et al, 2015), exosomes are potentially an excellent vehicle to deliver transdermal signaling molecules such as collagen and pro collagen.

Wound healing and maintenance of normal, unwounded skin involves multiple cell types and the specific sets of molecules that each of the multiple cell types release, including molecules from mesenchymal stem cells and fibroblasts that are resident in the skin tissue (Rodriguez-Menocal et al, 2012). When mammalian cells are in an environment unfavorable for continued proliferation, they can exit the cell cycle in early to mid-G₁ phase at the 'restriction point' (Pardee, 1974) and enter a reversible, out-of-cell cycle state defined as quiescence. The increased expression of ECM proteins such as Collagen I and III in fibroblasts is partly due to changes in expression of miRNAs such as miR-29 during their quiescent phenotype (Suh et al, 2012). Fibroblast switch their phenotype between two distinct states, proliferating and depositing ECM. Normally the fibroblasts do not proliferate (quiescence), but during wounding, the proliferating phenotype is necessary to maintain dermal architecture, although the architecture may be abnormal (scarring). The two cellular states are balanced by a negative feedback loop between ECM deposition/remodeling and proliferation (Rognoni et al, 2018). The phenotype of the fibroblasts can also be regulated by mesenchymal stem cells.

Whereas the quiescent state and collagen production in fibroblasts seems to be induced by adipose-derived mesenchymal stem cells (Liu et al, 2018), leading to scarless wound

healing (Wang et al, 2017), bone marrow derived mesenchymal stem cells (BMSCs) seem to induce proliferation, migration, and chemotaxis (Smith et al, 2010), and differentiation of resident stem cells to somatic cells (Maguire and Friedman, 2015) by releasing factors including Growth differentiation factor 11 (GDF11) (Williams et al. 2013). However, adipose derived mesenchymal stem cells release molecules, packaged in exosomes (Maguire, 2016b), that have been shown to switch the ratio of collagen I to collagen III from a scar-promoting high ratio to an anti-scarring low ratio, similar to that seen in fetal wound healing (Wang et al, 2017). Thus, for bloody, open wounds, where bone marrow stem cells are recruited to the skin, their function may be important for rapidly closing gaping wounds, inducing scars in the process, but may not be suited to finer wounds and the induction of scarless wound healing generated by endogenous mesenchymal stem cells in the skin, or derived from adipose tissue. Considering the continued use of a stem cell conditioned media based product using bone marrow stem cells (BMSCs), continued use of such a product would lead to long term over drive of the GDF11 controlled differentiation process and IGF-1 (Chen et al, 2008) induced cancer-like cellular proliferation (Renehan et al, 2004), and thus a deleterious effect by depletion of endogenous mesenchymal stem cells in the skin, a process called cellular exhaustion. Indeed, wound healing in skin does not increase the self-renewal capacities of progenitors as it does in the esophagus, but rather leads to a massive depletion of progenitor cells as proliferation increases (Aragona et al, 2017). This is in contradistinction to the molecules released by adipose derived stem cells that reduce the differentiation of stem cells, thus preserving the endogenous pool of stem cells and fibroblasts resident in the skin (Wang et al, 2017).

Physiological Renormalization – Why S2RM Treats Many Conditions

Physiological renormalization is a strategy recently developed for therapeutics to treat cancer. That is, renormalizing the physiology of T cells in the immune system instead of enhancement of the immune system or a direct attack on cancer cells is a new strategy in the successful development of a recently approved class of chemotherapeutics for cancer called “check point inhibitors” (Sanmamed and Chen, 2018). This is a strategy for which the 2018 Nobel Prize in Physiology or Medicine was awarded. In other words,

in this new strategy, the physiology of T-cells was renormalized so that the T-cells could once again function normally to attack the cancer, doing so for many cancer types (Zappasodi et al, 2018). Physiological renormalization is a process that occurs naturally, for example during sleep, during which spontaneous activity renormalizes net synaptic strength and restores cellular homeostasis (Tononi and Cirelli, 2014). As a next, and broader, step in the physiological renormalization strategy, we reperfused the skin with the collective of molecules, including proteins that were normally present in the skin during a healthy state. For example, in psoriasis, more than 1200 proteins with differentially expressed peptides many with biological functions of interest in psoriasis, and many in a misfolded state were identified in a mouse model and in human psoratic skin. And, over 100 proteins were changed greater than twofold comparing psoratic to healthy skin (Lundberg et al, 2015). In particular, considering the deregulation of T cells in psoriasis (Deng et al, 2016), our therapeutic contains the exosomes, and their protein cargo, that are derived from adipose mesenchymal stem cells, and have been shown to quell inflammation through regulation of T cells (Blazquez et al, 2014). Thus, in this study, we present evidence that physiological renormalization of proteostasis is an excellent strategy for treating psoriasis as well as a number of other conditions. This is not unlike physiological renormalization of the immune system with “checkpoint inhibitors” to treat an array of cancer types. This explains why in both cases one therapeutic will treat a number of indications; the S2RM technology and “checkpoint inhibitors,” induce a physiological state that is renormalized such that a number of indications involving physiological perturbations can be treated.

Limitations of Our Study

All of the cases reported here used an open label application of the NeoGenesis Recovery, and only some of the cases used a placebo control or comparator product. Therefore a direct comparison of rate and extent of the effects, such as wound closure, could not be quantified. Further, as substantiated by numerous studies, the placebo effect can be substantial, especially for indications such as pain (Ellingsen et al, 2013). Therefore, in our study quantification of the level of pain reduction by Recovery could not be performed. However, in our studies the patients had previously used other

products, in effect serving as a placebo control by which a comparison of pain level was made. In all cases where pain was a factor, Recovery was reported by the patient to have induced substantial pain relief as compared to the “placebo product,” such as Vaseline. Regression to the mean is another statistically important way in which a therapeutic effect can be mistaken for simple self healing (McDonald et al, 1983), especially for indications such as pain. In other words, if one tends to go for treatment when their condition is severe, and when their condition is at its worst or near worst, then with time later their condition will likely improve. The remediation of the indication over time is due to simple regression to the mean, something that can be much larger than that of placebo (O’Connell et al, 2015). As reviewed by the Royal Statistical Society, researchers are fooled all the time by regression to the mean, even when using blinded, randomized, placebo controlled trials (Senn, 2011). In recognition of this problem, in a number of our cases, the pain was ongoing, and the statistical regression to the mean was to the state of pain. Only when Recovery was applied did the pain reduce. Upon cessation of Recovery application, the pain reappeared. Likewise, the persistence of the scar for one year and then remediation of the scar in one month with the application of Recovery, demonstrates the scar removal was not simply self healing and a regression to the mean. It is important to understand factors other than treatment that can affect outcomes, including knowing the patterns of healing for a given indication (Artus et al, 2010). Knowing the pattern of disease will help us to determine causality (Pearl, 2018) by answering the counterfactual question: had the patient not had the S2RM administered, would she have experienced the same results? The Artus et al study showed that lower back pain diminished within many clinical trials in a given pattern, regardless of the treatment given, including placebo. In this regard, for example, radiation treatment for cancer always induces significant radiation dermatitis. In our three case studies where we administered the Recovery concurrently with the radiation treatment, we observed little or no radiation dermatitis. Thus, the Recovery treatment did not fit the pattern of the normal sequelae of skin damage and healing during and after the radiation treatment, suggesting a significant preventative effect of the Recovery, and not just a standard pattern of self healing. In other words, answering Pearl’s counterfactual question of causality (Pearl, 2018), “would the patient’s recovery

pattern have been the same had the S2RM not been applied to the patient,” the patient would not have recovered in the observed pattern shown in this study had they not received the S2RM technology. Therefore, despite the lack of controls in most cases, the benefit of Recovery was much better than patterns of self healing, regression to the mean, or placebo effects, that a large qualitative effect of Recovery was substantiated in real world outcomes. One important method for reducing variation in a study is to construct consistent and uniform endpoint definitions (Evans, 2011). In this regard, our study used easily observed, quantifiable measurements in most instances, except for measures of pain. For example, wrinkles are easily observed and objectively counted, color and darkness of skin were easily judged, and scarring could be easily judged even without rater training. Thus our data, conforming to the results of many previous studies using stem cells and their secretome, suggest that the S2RM technology, the secretome from multiple stem cell types, in a simple topical application is an effective treatment for traumatic, autoimmune, and inflammatory conditions of the skin. Our data suggest that a physiological renormalization strategy using topically applied stem cell released molecules is an important new clinical tool for a number of skin conditions.

References

1. Anderson A et al (2014) A role for human mitochondrial complex II in the production of reactive oxygen species in human skin. *Redox Biology*, 2: 1016-1022
2. Aragona M et al (2017) Defining stem cell dynamics and migration during wound healing in mouse skin epidermis. *Nat Commun*. 8: 14684.
3. Artus M et al (2010) Low back pain symptoms show a similar pattern of improvement following a wide range of primary care treatments: a systematic review of randomized clinical trials. *Rheumatology (Oxford)*. 49(12):2346-56.

4. Baumann BC et al (2018) Assessing the Validity of Clinician Advice That Patients Avoid Use of Topical Agents Before Daily Radiotherapy Treatments. JAMA Oncology, doi:10.1001/jamaoncol.2018.4292.

5. Belinchón I., Rivera R., Blanch C., Comellas M., Lizán L. (2016) Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: A systematic review of the literature. Patient Preference Adherence. 10:2357–2367. doi: 10.2147/PPA.S117006.

6. Blazquez R et al (2014) Immunomodulatory Potential of Human Adipose Mesenchymal Stem Cells Derived Exosomes on *in vitro* Stimulated T Cells. Front Immunol. 2014; 5: 556

7. Bowman A and Birch-Machin MA (2016) Age-Dependent Decrease of Mitochondrial Complex II Activity in Human Skin Fibroblasts. J Invest Dermatology 136: 912-919

8. Chen et al (2008) Paracrine Factors of Mesenchymal Stem Cells Recruit Macrophages and Endothelial Lineage Cells and Enhance Wound Healing. PLoS One. 3(4): e1886.

9. Chicharro D et al (2018) Combined plasma rich in growth factors and adipose-derived mesenchymal stem cells promotes the cutaneous wound healing in rabbits. BMC Vet Res. 14: 288.

10. Corstjens H, Dicanio D, Muizzuddin N, Neven A, Sparacio R, Declercq L, et al. (2008) Glycation associated skin autofluorescence and skin elasticity are related to chronological age and body mass index of healthy subjects. Exp Gerontol. 43:663–7. doi: 10.1016/j.exger.2008.01.012

11. Deng Y., Chang C., Lu Q. (2016) The inflammatory response in psoriasis: A comprehensive review. Clin. Rev. Allergy Immunol. 50:377–389. doi: 10.1007/s12016-016-8535-x.
12. Eckes B, Zweers MC, Zhang ZG, Hallinger R, Mauch C, Aumailley M, Krieg T (2006) Mechanical tension and integrin $\alpha 2 \beta 1$ regulate fibroblast functions. J Invest Dermatol Symp Proc 11: 66–72.
13. Ellingsen DM et al (2013) Placebo improves pleasure and pain through opposite modulation of sensory processing. Proc Natl Acad Sci U S A. 110(44): 17993–17998.
14. Eriksen JG, Kaalund I, Clemmensen O, Overgaard J, Pfeiffer P. (2017) Placebo-controlled Phase study II of vitamin K3 cream for the treatment of cetuximab-induced rash. **Support. Care Cancer** 25(7), 2179–2185.
15. Ernst O and Zor T (2010) Linearization of the bradford protein assay. J Vis Exp.(38). pii: 1918. doi: 10.3791/1918
16. Evans (2011) Fundamentals of clinical trial design. J Exp Stroke Transl Med. 3(1): 19–27.
17. Fuchs, E., and Green, H. (1978). The expression of keratin genes in epidermis and cultured epidermal cells. Cell 15, 887–897.
18. Fukuoka H, Suga H. (2015) Hair regeneration treatment using adipose-derived stem cell conditioned medium: follow-up with trichograms. Eplasty. 15:e10.
19. Gerstein AD, Phillips TJ, Rogers GS, Gilchrest BA (1993) Wound healing and aging. Dermatol Clin 11: 749–757.
20. Giangreco A et al (2008) Epidermal stem cells are retained *in vivo* throughout skin aging. Aging Cell. 1; 7(2): 250–259.

21. Gosain A, DiPietro LA (2004) Aging and wound healing. *World J Surg* 28: 321–326.

22. Goldberg B and Sherr CJ (1973) Secretion and extracellular processing of procollagen by cultured human fibroblasts. *Proc. Natl. Acad. Sci. USA*, 70:361–365.

23. Hofheinz R-D, Lorenzen S, Trojan J *et al.* (2018) EVITA—a double-blind, vehicle-controlled, randomized Phase trial II of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. *Ann. Oncol.*29(4), 1010–1015.

24. Hong J *et al* (2008) Difference gel electrophoresis analysis of Ras-transformed fibroblast cell-derived exosomes. *Electrophoresis*, <https://doi.org/10.1002/elps.200800015>

25. Hu L, Zhao J, Liu J, *et al.* (2013) Effects of adipose stem cell-conditioned medium on the migration of vascular endothelial cells, fibroblasts and keratinocytes. *Exp Ther Med.* 5(3):701–706.

26. Huang H, Qiu W, Zhu M, Zhang Y, Cui WH, Xing W, Li XY, An TC, Chen MJ, Guo W, Xu X. (2016) Expressions of the key proteins of the protein kinase B/mammalian target of rapamycin signaling pathway in skin tissue and wound tissue of diabetic rats. *Zhonghua Shao Shang Za Zhi.* 2016 Oct 20;32(10):588–593. doi: 10.3760/cma.j.issn.1009-2587.2016.10.004.

27. Hur W and Yoon SK (2017) Molecular Pathogenesis of Radiation-Induced Cell Toxicity in Stem Cells. *Int J Mol Sci.* 18(12): 2749.

28. Kurd SK, Gelfand JM (2009) The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. *J Am Acad Dermatol.* 60:218–224. doi: 10.1016/j.jaad.2008.09.022.

- 1
2
3 29. Liu X et al (2018) Exosomes secreted by adipose-derived mesenchymal stem
4 cells regulate type I collagen metabolism in fibroblasts from women with stress
5 urinary incontinence. *Stem Cell Research & Therapy* **9**:159
6
7
8
9
10 30. Lo Cicero A et al (2015) Exosomes released by keratinocytes modulate
11 melanocyte pigmentation. *Nature Communications*, **6**: 7506
12
13
14 31. Lundberg KC et al (2015) Proteomics of Skin Proteins in Psoriasis: From Discovery
15 and Verification in a Mouse Model to Confirmation in Humans. *Molecular & Cellular*
16 *Proteomics*, **14** (1) 109-119
17
18
19
20 32. Maguire G (2013) Stem cell therapy without the cells. *Commun Integr Biol.*
21 **6**(6):e26631.
22
23
24
25 33. Maguire G (2016) Therapeutics from Adult Stem Cells and the Hype Curve. *ACS*
26 *Med Chem Lett.* **7**(5):441-3.
27
28
29 34. Maguire G.. (2016b) Exosomes: Smart Nanospheres for Drug Delivery Naturally
30 Produced by Stem Cells. In *Fabrication and Self-Assembly of Nanobiomaterials*;
31 Elsevier: Amsterdam, 2016; pp 179–209.
32
33
34
35 35. Maguire G (2018) Stem Cell Released Molecules: A Paradigm Shift to Systems
36 Therapeutics. Nova Scientific Publishes, New York.
37
38
39 36. Maguire G et al (2018) Protein circuits in wound healing. *Science, eletters*,
40 **362**(6417).
41
42
43
44
45 37. Maguire G et al (2019) Rescue of Degenerating Neurons and Cells by Stem Cell
46 Released Molecules. *Physiological Reports*, In Press.
47
48
49
50
51 38. Maguire G (2019b) The Safe and Efficacious Use of Secretome From Fibroblasts
52 and Adipose-, But Not Bone Marrow-, Derived Mesenchymal Stem Cells For
53
54
55
56
57
58
59
60

Skin Therapeutics. In Press.

39. Mahmood and Bowe (2014) Diet and Acne Update: Carbohydrates Emerge as the Main Culprit. *J Drugs Dermatol.* 13(4):428-435.

40. Mascr  G, Dekoninck S, Drogat B, Youssef KK, Brohe  S, Sotiropoulou PA, et al. (2012) Distinct contribution of stem and progenitor cells to epidermal maintenance. *Nature.* 489(7415):257–62. pmid:22940863

41. Mauch C, Hatamochi A, Scharffetter K, Krieg T (1988) Regulation of collagen synthesis in fibroblasts within a three-dimensional collagen gel. *Exp Cell Res* 178: 493–503

42. McDonald CJ et al (1983) How much of the placebo effect is really statistical regression? *Statistics in Medicine*, 2: 417-427

43. Miller RC et al. (2011) Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the north central Cancer treatment group N06C4. *Int J Radiat Oncol Biol Phys.* 79(5):1460–1466. doi: 10.1016/j.ijrobp.2010.01.031

44. Nestle FO, et al. (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. *Journal of Experimental Medicine.* 202:135–143. doi: 10.1084/jem.20050500.

45. O’Connell NE et al (2015) Interpreting Effectiveness Evidence in Pain: Short Tour of Contemporary Issues. *Phys Ther.* 95:1087-1094

46. Owczarczyk-Saczonek A et al (2017) Stem Cells as Potential Candidates for Psoriasis Cell-Replacement Therapy. *Int J Mol Sci.* 18(10): 2182.

47. Pardee AB (1974) A restriction point for control of normal animal cell proliferation. *Proc Natl Acad Sci U S A.* 71(4):1286-90

48. Pearl J (2018) *The Book of Why. The New Science of Cause and Effect.* Basic Books, New York, NY.

49. Quan T, He T, Kang S, et al. (2004) Solar ultraviolet irradiation reduces collagen in photoaged human skin by blocking transforming growth factor-beta type II receptor/Smad signaling. *Am J Pathol.* 165(3):741–751.
50. Quan T, Wang F, Shao Y, Rittié L, Xia W, Orringer JS, Voorhees JJ, Fisher GJ (2013) Enhancing structural support of the dermal microenvironment activates fibroblasts, endothelial cells, and keratinocytes in aged human skin in vivo. *J Invest Dermatol* 133: 658–667.
51. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. *Lancet.* 363(9418):1346-7.
52. Rheinwald, J.G., and Green, H. (1975). Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. *Cell* 6, 331–343.
53. Rittié L, Berton A, Monboisse JC, Hornebeck W, Gillery P (1999) Decreased contraction of glycated collagen lattices coincides with impaired matrix metalloproteinase production. *Biochem Biophys Res Commun* 264: 488–492.
54. Rittie L and Fisher GJ (2015) Natural and Sun-Induced Aging of Human Skin. *Cold Spring Harb Perspect Med.* 5(1): a015370.
55. Rivera-Gonzalez G et al (2016) PDGFA regulation of dermal adipocyte stem cells. *Cell Stem Cell*, 4:72. doi: 10.21037/sci.2017.08.03
56. Rodriguez-Menocal L et al (2012) Stimulation of Skin and Wound Fibroblast Migration by Mesenchymal Stem Cells Derived from Normal Donors and Chronic Wound Patients. *Stem Cells Translational Medicine*, 1:221–229
57. Rognoni E et al (2018) Fibroblast state switching orchestrates dermal maturation and wound healing. *Molecular Systems Biology* 14, e8174.
58. Sanmamed MF and Chen L (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. *Cell*, 175: 313-326

59. Santer M et al. (2012) Experiences of carers managing childhood eczema and their views on its treatment: a qualitative study. *Br J Gen Pract* 62:e261–e267. 10.3399/bjgp12X636083

60. Senn S (2011) Francis Galton and regression to the mean. *Focus*, Sept. 2011, 124-126.

61. Sklirou AD et al (2017) 6-bromo-indirubin-3'-oxime (6BIO), a Glycogen synthase kinase-3 β inhibitor, activates cytoprotective cellular modules and suppresses cellular senescence-mediated biomolecular damage in human fibroblasts. *Sci Rep*. 7: 11713.

62. Smith J, Davidson E, Sams W, Clark R. (1962) Alterations in human dermal connective tissue with age and chronic sun damage. *J Invest Dermatol*. 39:347–350

62. Smith AN et al (2010) Mesenchymal stem cells induce dermal fibroblast responses to injury. *Exp Cell Res*. 316(1): 48–54.

63. Smith SD, Hong E, Fearn S, et al. (2010b) Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. *Australas J Dermatol* 51:168–74. 10.1111/j.1440-0960.2010.00636.x

64. Son WC, Yun JW, Kim BH. (2015) Adipose-derived mesenchymal stem cells reduce MMP-1 expression in UV-irradiated human dermal fibroblasts: therapeutic potential in skin wrinkling. *Biosci Biotechnol Biochem*. 79(6):919–925

65. Suh EJ et al (2012) A microRNA network regulates proliferative timing and extracellular matrix synthesis during cellular quiescence in fibroblasts. *Genome Biol*. 13(12): R121.

66. Swiecki M, Colonna M. (2010) Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. *Immunological Reviews*. 234:142–162. doi: 10.1111/j.0105-2896.2009.00881.x.
67. Taylor AP (2017) The Ever-Expanding T-Cell World: A Primer. *The Scientist*, Aug 7, 2017
68. Tononi G and Cirelli C (2014) Sleep and the Price of Plasticity: From Synaptic and Cellular Homeostasis to Memory Consolidation and Integration. *Neuron*. 81(1): 12–34.
69. Turlier V, Delalleau A, Casas C, Rouquier A, Bianchi P, Alvarez S, Josse G, Briant A, Dahan S, Saint-Martory C, et al (2013) Association between collagen production and mechanical stretching in dermal extracellular matrix: In vivo effect of cross-linked hyaluronic acid filler. A randomised, placebo-controlled study. *J Dermatol Sci* 69: 187–194.
70. Waibel JS, Wulkan AJ, Shumaker PR. (2013) Treatment of hypertrophic scars using laser and laser assisted corticosteroid delivery. 45(3):135–40.
71. Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ, Voorhees JJ (2007) In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. *Arch Dermatol* 143: 155–163
72. Wang L et al (2017) Exosomes secreted by human adipose mesenchymal stem cells promote scarless cutaneous repair by regulating extracellular matrix remodeling. *Scientific Reports* 7, Article number: 13321
73. Weidinger S and Novak N. (2016) Atopic dermatitis. *The Lancet* 387:1109–22. 10.1016/S0140-6736(15)00149-X
74. Williams G, Zentar MP, Gajendra S, Sonogo M, Doherty P, Lalli G. (2013) Transcriptional basis for the inhibition of neural stem cell proliferation and migration by the TGF β -family member GDF11. *PLoS One*, 8:e78478.

75. Wohn, C. *et al.* (2013) Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 10723–10728, 10.1073/pnas.1307569110.

76. Yamazaki H *et al* (2018) Comparison of radiation dermatitis between hypofractionated and conventionally fractionated postoperative radiotherapy: objective, longitudinal assessment of skin color. *Sci Rep.* 2018; 8: 12306.

77. Zappasodi R *et al* (2018) Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. *Cancer Cell.* 33(4):581-598

Physiological Renormalization of Skin in Traumatic, Irradiation, Autoimmune, and Aging Conditions Using S2RM Stem Cell Released Molecules Enhances Healing and Reduces Pain

Greg Maguire^{1@}, Ph.D., Steven McGee¹, Lee Paler¹, Linda Green¹, Holly Brown²,
Geraldyn O'Brien³, Tracy Lacina⁴, Donna Glazer,⁵ Valentin Isecescu, M.D.⁶

1. NeoGenesis Inc, San Diego, CA 92121 USA; 2. Looking and Feeling FAB, Inc, 3.
Integrative Cancer Review, 4. Skin Deep Salon & Spa, 5. Faceit London, London UK, 6.
North County Clinical Research, Oceanside, CA 92056 USA

@ Corresponding author

Greg Maguire, Ph.D.

NeoGenesis Inc

11588 Sorrento Valley Road #18

San Diego, CA 92121 USA

Email: gmaguire@neogenesis.com

Phone: 858-413-7372

Key Words: Stem Cells, Skin Trauma, Skin Disease, Proteins

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Your manuscript needs revision before it is sent to review. Please include the corresponding author's contact information on the title page. Please also list 3-5 keywords. The entire manuscript including the references must be double spaced. Add page numbers to the top right of each page. The figures must be removed from the main document. Each figure should be saved separately and each figure should be formatted as a jpg, tiff or eps file. A legend to the figures should be in the main document after the references. After these changes are made, resubmit your manuscript to JDT.

Please visit the instructions to authors to complete your submission and re-submit the manuscript for consideration of publication

For Peer Review Only

Abstract

Wounds, aging, and autoimmune conditions of the skin involve a disruption of skin homeostasis, especially a disruption of proteostasis. In this study we used S2RM

technology, a proprietary combination of stem cell released molecules from multiple types of skin stem cells, to renormalize homeostasis of the skin, including a renormalization of proteostasis. Dramatic reductions in scarring, pain, redness, and inflammation, more rapid and complete wound healing, and an overall enhancement of the appearance of the skin were achieved in a number of skin conditions. Prevention of radiation dermatitis was achieved by concurrent topical administration of S2RM during radiation treatment. The current study demonstrates that simple topical application of S2RM technology is a powerful means to renormalize homeostasis of the skin, and remediate and prevent a number of skin indications.

Introduction

Multiple types of stem and progenitor cells are resident in the skin to maintain the skin's physiology and structure (Fuchs and Green, 1978; Mascre et al, 2012). Recently the importance of proteostasis in the skin (Skirou et al, 2017) and the molecules, such as PDGF, that stem cells release in healing tissue has been recognized (Maguire, 2013), particularly in the skin (Rivera-Gonzalez et al, 2016) for the development of therapeutics that mimic and facilitate protein circuits for wound healing (Maguire, 2018). In 1975, Howard Green at MIT showed for the first time that identified cells, what he called human keratinocytes, and what we now define as stem cells, could be passaged clonally for hundreds of generations without losing their diploidy or their ability to make tissue (Rheinwald and Green, 1975). Later recognized was that stem cells could be passaged in the laboratory in such a manner as to collect the molecules that they release for means of therapeutic development (Maguire, 2016). In this way, the major therapeutic benefit of stem cells, acting through the many molecule types that they

release (Maguire, 2013), could be applied directly to the patient without the vagaries associated with using the stem cells themselves (Maguire, 2016).

The conditioned medium containing growth factors, cytokines, and other molecules, secreted, not extracted, by stem cells has demonstrated efficacy in rescuing cells from a variety of stress factors (Maguire et al, 2019) enhancing hair growth (Fukuoka and Suga, 2015), alteration of matrix metalloproteinase (MMP) expression in dermal fibroblasts that have been exposed to ultraviolet radiation (Son et al, 2015); controlling collagen production, modulating endothelial cell, fibroblast, and keratinocyte migration (Hu et al, 2013), and improving scarless wound healing (Wang et al, 2017; Chicharo et al, 2018). These phenomena may have potential benefit in addressing aged skin conditions, cutaneous wound healing, photodamage and subsequent wrinkling and elastosis, and scarless wound healing. The choice of stem cell type is crucial for the development of a safe and efficacious secretome to be used in skin care products, such that skin derived stem cells should be used and not bone marrow stem cells (Maguire, 2019b).

Chronologically aged skin is thin, dry, and finely wrinkled, while photoaged skin typically appears leathery, lax, with coarse wrinkles, “broken”-appearing blood vessels (telangiectasia), and uneven pigmentation with brown spots (lentigines) and yellowish color due to advanced glycation end products (Corstjens et al, 2008). Histologically, both aged and photoaged skin display epidermal differences compared to normal skin. Effects of natural aging and photoaging on the dermis are also profound and involve deleterious alterations to the collagenous extracellular matrix. Evidence indicates that accumulation of fragmented dermal extracellular matrix (ECM) is a key factor that

mediates many of the characteristic features of aged human skin (Rittie and Fisher, 2015).

In aging skin, facial rhytides are common and are of concern to many patients seen at dermatology clinics. The cause of facial wrinkles is multifactorial involving accumulated photodamage, muscular hyperactivity, age-related volume loss, and diminution of stem cell function in aged skin. Complex II activity within mitochondria is significantly decreased with age in fibroblasts, but not in keratinocytes (Bowman and Birch-Machin, 2016). Complex II in mitochondria are a powerful regulator of reactive oxygen species (ROS) and have a two-fold greater activity in skin compared to liver (Anderson et al, 2014). Ultraviolet radiation causes increased oxidative stress leading to DNA damage, tissue damage, and the accumulation of reactive oxygen species, resulting in reduced procollagen synthesis in human skin fibroblasts (Quan et al, 2004). Damage to skin connective tissues derived from fibroblasts is responsible for the characteristic aged appearance of photodamaged skin (Smith et al, 1962).

Wound repair is an elaborate and continuous process that can be thought of, in an oversimplified manner, as three overlapping phases, the inflammatory, proliferative, and remodeling phases. Age-related changes in wound repair have been described in each of these phases (Gerstein et al. 1993; Gosain and DiPietro 2004). Reduced expression of the epidermal stem cell markers melanoma chondroitin sulfate proteoglycan and integrin β 1 has been observed in human skin, while some stem cell numbers remained constant, suggestive of disruption of proteostasis in aged skin and not a simple diminution of skin cell numbers (Giangreco et al. 2008). Thus targeting the disruption of proteostasis with a proteostatic renormalization strategy may be warranted.

Our studies here showed that the stem cell released molecules (S2RM) from multiple types of stem cells derived from human skin, used as a means to renormalize proteostasis of the skin, were well tolerated in human subjects as demonstrated by a Human Insult Repeat Patch Test (HIRPT), and proved highly efficacious in treating or preventing a number of skin conditions, including aged skin, dermatitis, including radiation dermatitis, trauma, acne, and autoimmune related issues.

Methods

Stem Cell released Molecules

A proprietary collection of stem cell lines derived from human skin were cultured using no penicillin/streptomycin under hypoxic conditions. When cultures reached confluence, they were passaged for a limited number of times before disuse. Total conditioned medium from the multiple cell types, containing a soluble fraction and an exosome fraction, was harvested at each passage and the passages combined into one batch for product development. Parts of our stem cell technology used here are covered by US patents: 9545370; 9446075; 20140205563; 20130302273.

Case Studies

In all cases an open label application of NeoGenesis Recovery was used to treat the skin condition. Simple topical administration to the affected area without other products or procedures was utilized.

Safety Studies, HRIPT

We used the Human Repeat Insult Patch Test (McNamee et al, 2008) to assess primary and accumulative irritation, and/or allergic contact sensitization, in human subjects, male and female, between the ages of 18 and 66. All subjects were free of skin disease, and were prohibited from using topical or systemic antihistamines and steroids beginning seven days prior to the onset and throughout the duration of the study. Measurements were performed by a trained rater technician. For the induction phase of the study, the patches of 0.1 g of S2RM per 1X1 inch square Webril dressing, were applied 3 times weekly for 3 weeks for a total of 9 applications. The patches were removed 48 hours after application and evaluated before the a fresh patch was reapplied to the same area. For the challenge phase of the study, two weeks after the final induction phase patch was applied, an adjacent, virgin area of skin then received a fresh patch and was evaluated at 24 and 72 hours following application of the patch. Ratings were scored using the following table:

- 0 – No visible skin reaction
- + - Barely perceptible or spotty erythema
- 1- Mild erythema covering most of the test site
- 2- Moderate erythema, possible mild edema
- 3- Marked erythema, possible edema
- 4- Severe erythema, possible edema, vesiculation, bullae, and/or ulceration

Results

Batch Reproducibility – Total protein

The method of Bradford was used in all protein determinations (Ernst and Zor, 2010).

The Bradford protein assay is a spectroscopic analytical procedure used to measure the concentration of protein in a solution. Samples, performed in duplicate, from a total of 15 batches of S2RM were analyzed. The variation between duplicates in all cases was less than 10%. Five samples of different S²RM batches, and 5 samples of the individual batches of SRM from the individual cell lines that make-up the S²RM, were analyzed for total protein. All samples were taken from frozen aliquots of batches previously used to make skin care products with demonstrated efficacy. All batches produced at least 500 ug/ml of total protein, with a high value in one batch of 630 ug/ml. The mean value of all batches was 554 ug/ml. The variability in all the batches was 20% or less. With the exception of one batch displaying a high protein count (630ug/ml), the rest of the batches had a variability of 12% or less.

Skin Safety Testing, Irritation

Ninety-one (91) qualified subjects, male and female, ranging in age from 18 to 66 years, were selected for this evaluation. Fifty (50) subjects completed the study. The remaining subjects discontinued their participation for various reasons, none of which were related to the application of the test material. Of the 50 subjects completing the study, all were rated at 0 during both the induction phase and the challenge phase, indicating that the S2RM induced no immediate or long term irritation, or allergic reaction.

Skin Testing Efficacy, Case Studies

We used topical application of the stem cell based S2RM technology to treat a number of skin conditions involving trauma, autoimmunity, and aging. All procedures used an open label topical application of NeoGenesis Recovery, containing 70% of the S2RM material.

1. Traumatic Wounds

For analysis of traumatic wounds, we treated patients with scalpel surgery or wounds from traumatic accidents. In Figure 1 a patient had a tumor about the size of a ping pong ball (about 40mm in diameter) removed from her leg, leaving a large void and a very large incision. The patient was upset by the appearance of the wound, and her physician recommended using NeoGenesis' Recovery to aid the closure and for anti-scarring benefit. One year post-surgery there was complete healing, normal remodeling of the tissue and extracellular matrix, with no scarring.

In another subject (Fig.2) who had experienced traumatic wounds to his head, legs, torso, arms and hands due to a bicycle accident, the patient used Recovery for more complete and faster healing. As a competitive bicycle racer, he had been in previous like accidents, and compared his healing using Recovery to past experiences. He also suggested himself to compare the healing effects of Recovery versus no treatment by using Recovery on one hand, but not the other. Both arms and hands were lacerated and bleeding to a similar degree. Twice daily application of Recovery to the arm was

1
2
3 compared to the left hand control. An obvious faster and more complete wound healing
4
5 was observed using Recovery on the arm (Fig. 2 A and B) compared to not using
6
7 Recovery on the hand (Fig. 2 C and D).
8
9

10 11 **2. Radiation Treatment and Chemical Peel** 12

13 Prior to radiation treatment, a plastic surgeon removed the scar tissue from the patient's
14
15 breast that had resulted from a lumpectomy. Unfortunately, the patient simultaneously
16
17 opted to include an elective procedure of a laser and chemical peel, resulting in severe
18
19 blistering and burning (Figure 3A). About 3 weeks later the patient began radiation
20
21 treatment for cancer. Recovery was used twice daily and no peeling, blistering, or
22
23 scarring was observed. Her skin darkened for about 10 days, and then dissipated. The
24
25 results were especially surprising to the attending physician and nurses given the
26
27 patient also suffers from Lupus, making her very sensitive to these treatments.
28
29
30
31
32
33
34
35

36 **3. Post LASER Recovery** 37

38 LASER treatment for chronologically aged skin and scarring is common. Fractional
39
40 ablative lasers create zones of ablation at variable depths in the layers of skin with
41
42 subsequent induction of collagen production, wound healing, and collagen remodeling.
43
44 Recent studies suggest that the ablative zones in the skin may also be used in the
45
46 immediate postoperative period to enhance delivery of drugs and other substances
47
48 such as platelet-rich plasma or stem cell released molecules (Waibel et al, 2013). We
49
50 therefore used the NeoGenesis stem cell released molecule-based product during the
51
52 immediate postoperative period as a twice daily topically applied procedure. The
53
54
55
56
57
58
59
60

inflammation, pain, and redness were dramatically reduced in three patients using the Recovery product. Those practitioners administering the procedure also observed an increased efficacy with coadministration of the S2RM product.

4. Atopic Dermatitis (Eczema)

Atopic eczema, also known as atopic dermatitis and commonly referred to as eczema, is a long-term relapsing skin condition that causes both physical and psychological suffering and can have a detrimental impact on quality of life for individuals and their family. The disease is one of the 50 most burdensome globally (Weideinger and Novak, 2016). The mainstay treatments include regular and consistent application of topical medication, predominantly emollients and steroid preparations (Santer et al, 2012). Treatment failure is common leading to wastage of the prescriptions (Smith et al, 2010b). We presented the subject with an easy to use topically applied product applied twice daily. One patient presented in Figure 4 had suffered with the rash as shown for over twenty years. Within 30 days of the treatment with the S2RM product, the rash and pruritis had significantly reduced in severity.

5. LASER treatment with postoperative Recovery versus standard of care.

To test whether our S2RM-based product would provide superior postoperative care to LASER patients compared with the standard of care, we applied Recovery on one hand and the standard of care on the other hand of one patient who had both hands treated equally with LASER. The photos demonstrate a reduction in redness of the Recovery

1
2
3 treated hand compared to the control hand treated with the standard of care. The
4
5 patient also reported a significant reduction in pain using Recovery compared to the
6
7 control.
8
9

10 11 12 13 14 **6. Psoriasis**

15
16 Psoriasis is a chronic autoimmune condition affecting approximately 2% of the
17
18 population (Kurd and Gelfand, 2012). While the cause of psoriasis is unknown, hyper-
19
20 reactivity of Th1, Th17, dysregulation of Treg, and the complex relationships between
21
22 immune system cells and keratinocytes and vascular endothelium play a significant role
23
24 (Deng et al, 2016). Thus in psoriasis, hyperactivity of Th1 and Th17 means that T cells
25
26 are activated against viral and bacterial infection, activating macrophages, and
27
28 dysregulation of Treg means that the activation of Th1 and Th17 may be misguided and
29
30 uncontrolled (for a short review see Taylor, 2017). Evidence also shows that
31
32 plasmacytoid dendritic cells (pDC) may be central to disease development (Wohn et al,
33
34 2013). The pDCs produce about 1000 times more type I interferon (IFN-I) than any
35
36 other cell type (Nestle et al, 2005), and account for about 50% of all circulating IFN-I
37
38 following infection (Swiecki and Colonna, 2010). Nestle et al (2005) have proposed that
39
40 pDCs in hereditary predisposed individuals subject to certain environmental conditions
41
42 acting through the secretion of IFN-I, induce autoimmune T cells that elicit a
43
44 psoriasiform phenotype (Nestle et al, 2005). Currently there is no fully satisfactory
45
46 therapy against psoriasis and patients frequently report dissatisfaction with the
47
48 treatment (Belinchón et al, 2016). A number of studies suggest that stem cell therapy
49
50 may be useful in the treatment of psoriasis (Owczarczyk-Saczonek et al, 2017).
51
52
53
54
55
56
57
58
59
60

Because the efficacy of stem cell therapy is often ascribed to the molecules and exosomes released by the stem cells (Maguire, 2013; Maguire, 2016), we used topical S2RM technology to treat the psoriasis.

Using a twice daily topical application of Recovery, the subject began to see a reduction in redness and pruritis within one week. By day 42 as shown in Figure 6, the patient had a near eradication of the psoriasis that was presenting on his arms and elbows.

7. Recovery From Radiation Treatment for Cancer

Skin color changes are key biomarker for the ill effects of irradiation on the skin during breast cancer treatment, and darkening of the skin correlates in a linear manner with the maximal dosage of irradiation (Yamazaki et al, 2018). Irradiated skin shows a number of changes, including damage of the dermal stem cells and fibroblasts (Hur and Yoon, 2017). Miller et al (2012) have shown the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in 176 patients undergoing breast or chest wall radiotherapy. Results showed no difference between treatment and placebo when the mean maximum grade of radiation dermatitis was used as primary endpoint, but did show a reduction in the mean grade of discomfort or burning. Because of the ability of the S2RM technology to quell inflammation and pain, and to rebuild tissue, we used a topical application of Recovery twice daily to treat radiation dermatitis. Figure 7 shows one such patient treated following the completed radiation therapy protocol. A total of 33

1
2
3 treatments of proton radiation were received between Aug 2017 and Sept 2017. She
4
5 underwent two lumpectomies followed by a mastectomy and four rounds of
6
7 chemotherapy. Within two days of topically applying Recovery, the patient began to feel
8
9 a reduction in pain and sensitivity of the treated area.
10
11
12
13
14
15

16 17 **8. Fluorouracil (5-FU) Treatment**

18
19 Fluorouracil is commonly given systemically for anal, breast, colorectal, oesophageal,
20
21 stomach, pancreatic and skin cancers, as well as topically for some skin cancers.
22
23 Frequent side effects include inflammation of the mouth, loss of appetite, low blood cell
24
25 counts, hair loss, and inflammation of the skin. The patient in Figure 8 was prescribed
26
27 topical fluorouracil for 30 days. Experiencing severe pruritis, pain, bleeding, and
28
29 significant wounds on a large area of her face (Pictures on the left column), and having
30
31 been recommended to use Vaseline by medical care team, she reached out to her
32
33 esthetician for help with the itching and wounds. Recovery was applied twice daily, and
34
35 as shown in the pictures on the right column, the severity of the wounds and the
36
37 bleeding was greatly mitigated in 24 hours. Her pruritis and pain were self reported to
38
39 be “greatly reduced.”
40
41
42
43
44
45
46
47
48
49
50

51 **9. Prevention of Radiation Dermatitis Using Recovery During Radiation** 52 53 **Treatment** 54 55 56 57 58 59 60

Given that post radiation treatment with Recovery was highly effective in several patients, several new patients were presented to us before their radiation treatment began in the hope that the S2RM technology would prevent, or mitigate, the induction of radiation dermatitis. Although some physicians still recommend patients not apply topical products before radiation treatment, topical application of products just before radiotherapy is safe and not contraindicated (Baumann et al, 2018). With concurrent administration of Recovery twice daily during radiation treatment the patient's skin did not darken or become red, indicating that the Recovery was preventing radiation dermatitis. Healing of the scar from scalpel surgery of the breast was also enhanced.

10. Chemo Associated Rash

Cancer patients are often found in the hospice, and palliative care is critical to their well being. A number of drugs used in cancer treatment can cause skin problems, including rashes. One drug example is EGFR (epidermal growth factor receptor) inhibitors. These drugs are often prescribed for patients with colon, head and neck, pancreatic, non-small cell lung, and breast cancers. A number of this class of drug are available, including cetuximab (Erbix), panitumumab (Vectibix), erlotinib (Tarceva), gefitinib (Iressa), and lapatinib (Tykerb/Tyverb). Although topical vitamin K3 was proposed to provide benefit as a prophylactic for cetuximab-induced rash in patients with metastatic colorectal cancer, a recent Phase II, placebo-controlled study of vitamin K3 cream did not support any clinical or immunohistochemical benefit (Eriksen et al, 2017). Similarly, in a recent Phase II, double-blind, vehicle controlled study, vitamin K1 cream as prophylaxis for

1
2
3 cetuximab-induced skin toxicity did not reduce the incidence of grade ≥ 2 skin rash
4
5 (Hofheinz et al, 2018).
6
7

8
9 One patient experiencing chemotherapy induced rash used NeoGenesis Recovery
10
11 serum applied topically twice a day to the affected areas. In one week, a self reported
12
13 significant improvement was achieved. The redness of the rash faded, the raised areas
14
15 diminished, the blisters went away, and the pruritis completely stopped. The patient
16
17 reported, "Recovery serum is a miracle product. I highly recommend it to anyone with
18
19 skin issues from chemo."
20
21
22
23
24
25

26 **11. Old Scar Remediation**

27
28 We tested Recovery in one subject who had a one year old scar that had resulted from
29
30 a Fraxel Laser resurfacing procedure. The appearance of the scar had remained stable
31
32 for one year. After one year, topical application of Recovery twice daily resulted in a
33
34 significant reduction in the scar as shown in Figure 11. This was not a thick scar with a
35
36 raised surface area, rather appeared as an atrophic scar with red and dark
37
38 hyperpigmentation.
39
40
41
42
43
44
45

46 **12. Chronologically aged skin**

47
48 We tested the effects of Recovery on the chronological aging of the skin in twenty
49
50 subjects. Topical application of Recovery was done twice daily. We saw an average
51
52 67% reduction in the number of lines, with a range between 57% and 75% reduction.
53
54 Measurements were made of the crow's feet lines surrounding the eyes. Although the
55
56
57
58
59
60

1
2
3rater visually observed a reduction in lines in other parts of the face, no quantification
4
5was performed in those areas.
6
7
8
9

10
11
12**13.Acne**
13

14Pathogenesis of acne is characterized by androgen-stimulated overproduction of
15
16sebum, follicular hyperkeratinization, inflammatory mediators, and colonization by
17
18organisms such as *Propionibacterium acnes*. The etiology of acne is not well
19
20understood. While hereditary factors, including genetics may influence a patient’s risk
21
22of developing acne, the prevalence of adult acne in the US is increasing over the last
23
24few decades, where significant hereditary changes, or germline genetic variants are
25
26unlikely. Rather, environmental conditions, including diet, likely underlie the
27
28multifactorial etiology of acne (Mahmood and Bowe, 2014) In the medical setting, the
29
30standard of care for inflammatory acne is often a combination therapy including a
31
32retinoid and benzoyl peroxide. For moderate-to-severe cases, an oral antibiotic is also
33
34often prescribed, usually for no more than 4 months. Given the inflammatory and
35
36cellular perturbation in acneic skin, we used Recovery, a stem cell conditioned media
37
38product containing product topically applied to the affected area.
39
40
41
42
43

44
45Recovery was tested on four acne patients with results typified in Figure 13. Using a
46
47topical application of Recovery twice daily, acne breakout was shown to diminish in all 4
48
49subjects within two months.
50
51
52
53
54
55
56
57
58
59
60

Discussion

Restoration of the skin's extracellular matrix (ECM), and considering only the structural and mechanical properties of the dermal extracellular matrix, is critical to dermal maintenance and repair. In vitro studies show that fibroblasts in a mechanically stiffer environment produce more collagen and fewer MMPs than fibroblasts cultured in a more flexible collagen matrix (Mauch et al. 1988; Rittié et al. 1999; Eckes et al. 2006). Further, studies of human skin have shown that local increase in mechanical forces within the dermis can reprogram fibroblasts to up-regulate collagen production in vivo (Wang et al. 2007; Quan et al. 2013), of which the correlative effects can be observed clinically in human subjects through the addition of collagen to the dermis using dermal filler injections (Turlier et al, 2013). Although fibroblasts and mesenchymal stem cells are known to secrete procollagen and collagen (Goldberg and Sherr, 1973; Amable et al, 2014), whether the effects we observed in this study were partially due to the topical application of secreted pro collagen and collagen is unknown. In favor of this suggestion, fibroblasts have been shown to secrete exosomes that contain collagen (Hong et al, 2008). As lipophyllic structures that are known to deliver signals in the keratinocyte layer (Lo Cicero et al, 2015), exosomes are potentially an excellent vehicle to deliver transdermal signaling molecules such as collagen and pro collagen.

Wound healing and maintenance of normal, unwounded skin involves multiple cell types and the specific sets of molecules that each of the multiple cell types release, including molecules from mesenchymal stem cells and fibroblasts that are resident in the skin tissue (Rodriguez-Menocal et al, 2012). When mammalian cells are in an environment unfavorable for continued proliferation, they can exit the cell cycle in early to mid-

G₁ phase at the 'restriction point' (Pardee, 1974) and enter a reversible, out-of-cell cycle state defined as quiescence. The increased expression of ECM proteins such as Collagen I and III in fibroblasts is partly due to changes in expression of miRNAs such as miR-29 during their quiescent phenotype (Suh *et al*, 2012). Fibroblast switch their phenotype between two distinct states, proliferating and depositing ECM. Normally the fibroblasts do not proliferate (quiescence), but during wounding, the proliferating phenotype is necessary to maintain dermal architecture, although the architecture may be abnormal (scarring). The two cellular states are balanced by a negative feedback loop between ECM deposition/remodeling and proliferation (Rognoni *et al*, 2018). The phenotype of the fibroblasts can also be regulated by mesenchymal stem cells. Whereas the quiescent state and collagen production in fibroblasts seems to be induced by adipose-derived mesenchymal stem cells (Liu *et al*, 2018), leading to scarless wound healing (Wang *et al*, 2017), bone marrow derived mesenchymal stem cells (BMSCs) seem to induce proliferation, migration, and chemotaxis (Smith *et al*, 2010), and differentiation of resident stem cells to somatic cells (Maguire and Friedman, 2015) by releasing factors including Growth differentiation factor 11 (GDF11) (Williams *et al*. 2013). However, adipose derived mesenchymal stem cells release molecules, packaged in exosomes (Maguire, 2016b), that have been shown to switch the ratio of collagen I to collagen III from a scar-promoting high ratio to an anti-scarring low ratio, similar to that seen in fetal wound healing (Wang *et al*, 2017). Thus, for bloody, open wounds, where bone marrow stem cells are recruited to the skin, their function may be important for rapidly closing gaping wounds, inducing scars in the process, but may not be suited to finer wounds and the induction of scarless wound healing generated by

1
2
3 endogenous mesenchymal stem cells in the skin, or derived from adipose tissue.

4
5 Considering the continued use of a stem cell conditioned media based product using
6
7 bone marrow stem cells (BMSCs), continued use of such a product would lead to long
8
9 term over drive of the GDF11 controlled differentiation process and IGF-1(Chen et al,
10
11 2008) induced cancer-like cellular proliferation (Renehan et al, 2004), and thus a
12
13 deleterious effect by depletion of endogenous mesenchymal stem cells in the skin, a
14
15 process called cellular exhaustion. Indeed, wound healing in skin does not increase the
16
17 self-renewal capacities of progenitors as it does in the esophagus, but rather leads to a
18
19 massive depletion of progenitor cells as proliferation increases (Aragona et al, 2017).
20
21 This is in contradistinction to the molecules released by adipose derived stem cells that
22
23 reduce the differentiation of stem cells, thus preserving the endogenous pool of stem
24
25 cells and fibroblasts resident in the skin (Wang et al, 2017).
26
27
28
29
30

31 **Physiological Renormalization – Why S2RM Treats Many Conditions**

32
33
34 Physiological renormalization is a strategy recently developed for therapeutics to treat
35
36 cancer. That is, renormalizing the physiology of T cells in the immune system instead of
37
38 enhancement of the immune system or a direct attack on cancer cells is a new strategy
39
40 in the successful development of a recently approved class of chemotherapeutics for
41
42 cancer called “check point inhibitors” (Sanmamed and Chen, 2018). This is a strategy
43
44 for which the 2018 Nobel Prize in Physiology or Medicine was awarded. In other words,
45
46 in this new strategy, the physiology of T-cells was renormalized so that the T-cells could
47
48 once again function normally to attack the cancer, doing so for many cancer types
49
50 (Zappasodi et al, 2018). Physiological renormalization is a process that occurs naturally,
51
52 for example during sleep, during which spontaneous activity renormalizes net synaptic
53
54
55
56
57
58
59
60

strength and restores cellular homeostasis (Tononi and Cirelli, 2014). As a next, and broader, step in the physiological renormalization strategy, we reperfused the skin with the collective of molecules, including proteins that were normally present in the skin during a healthy state. For example, in psoriasis, more than 1200 proteins with differentially expressed peptides many with biological functions of interest in psoriasis, and many in a misfolded state were identified in a mouse model and in human psoratic skin. And, over 100 proteins were changed greater than twofold comparing psoratic to healthy skin (Lundberg et al, 2015). In particular, considering the deregulation of T cells in psoriasis (Deng et al, 2016), our therapeutic contains the exosomes, and their protein cargo, that are derived from adipose mesenchymal stem cells, and have been shown to quell inflammation through regulation of T cells (Blazquez et al, 2014). Thus, in this study, we present evidence that physiological renormalization of proteostasis is an excellent strategy for treating psoriasis as well as a number of other conditions. This is not unlike physiological renormalization of the immune system with “checkpoint inhibitors” to treat an array of cancer types. This explains why in both cases one therapeutic will treat a number of indications; the S2RM technology and “checkpoint inhibitors,” induce a physiological state that is renormalized such that a number of indications involving physiological perturbations can be treated.

Limitations of Our Study

All of the cases reported here used an open label application of the NeoGenesis Recovery, and only some of the cases used a placebo control or comparator product. Therefore a direct comparison of rate and extent of the effects, such as wound closure, could not be quantified. Further, as substantiated by numerous studies, the placebo

effect can be substantial, especially for indications such as pain (Ellingsen et al, 2013). Therefore, in our study quantification of the level of pain reduction by Recovery could not be performed. However, in our studies the patients had previously used other products, in effect serving as a placebo control by which a comparison of pain level was made. In all cases where pain was a factor, Recovery was reported by the patient to have induced substantial pain relief as compared to the “placebo product,” such as Vaseline. Regression to the mean is another statistically important way in which a therapeutic effect can be mistaken for simple self healing (McDonald et al, 1983), especially for indications such as pain. In other words, if one tends to go for treatment when their condition is severe, and when their condition is at its worst or near worst, then with time later their condition will likely improve. The remediation of the indication over time is due to simple regression to the mean, something that can be much larger than that of placebo (O’Connell et al, 2015). As reviewed by the Royal Statistical Society, researchers are fooled all the time by regression to the mean, even when using blinded, randomized, placebo controlled trials (Senn, 2011). In recognition of this problem, in a number of our cases, the pain was ongoing, and the statistical regression to the mean was to the state of pain. Only when Recovery was applied did the pain reduce. Upon cessation of Recovery application, the pain reappeared. Likewise, the persistence of the scar for one year and then remediation of the scar in one month with the application of Recovery, demonstrates the scar removal was not simply self healing and a regression to the mean. It is important to understand factors other than treatment that can affect outcomes, including knowing the patterns of healing for a given indication (Artus et al, 2010). Knowing the pattern of disease will help us to determine causality

(Pearl, 2018) by answering the counterfactual question: had the patient not had the S2RM administered, would she have experienced the same results? The Artus et al study showed that lower back pain diminished within many clinical trials in a given pattern, regardless of the treatment given, including placebo. In this regard, for example, radiation treatment for cancer always induces significant radiation dermatitis. In our three case studies where we administered the Recovery concurrently with the radiation treatment, we observed little or no radiation dermatitis. Thus, the Recovery treatment did not fit the pattern of the normal sequelae of skin damage and healing during and after the radiation treatment, suggesting a significant preventative effect of the Recovery, and not just a standard pattern of self healing. In other words, answering Pearl’s counterfactual question of causality (Pearl, 2018), “would the patient’s recovery pattern have been the same had the S2RM not been applied to the patient,” the patient would not have recovered in the observed pattern shown in this study had they not received the S2RM technology. Therefore, despite the lack of controls in most cases, the benefit of Recovery was much better than patterns of self healing, regression to the mean, or placebo effects, that a large qualitative effect of Recovery was substantiated in real world outcomes. One important method for reducing variation in a study is to construct consistent and uniform endpoint definitions (Evans, 2011). In this regard, our study used easily observed, quantifiable measurements in most instances, except for measures of pain. For example, wrinkles are easily observed and objectively counted, color and darkness of skin were easily judged, and scarring could be easily judged even without rater training. Thus our data, conforming to the results of many previous studies using stem cells and their secretome, suggest that the S2RM technology, the secretome

from multiple stem cell types, in a simple topical application is an effective treatment for traumatic, autoimmune, and inflammatory conditions of the skin. Our data suggest that a physiological renormalization strategy using topically applied stem cell released molecules is an important new clinical tool for a number of skin conditions.

References

1. Anderson A et al (2014) A role for human mitochondrial complex II in the production of reactive oxygen species in human skin. *Redox Biology*, 2: 1016-1022
2. Aragona M et al (2017) Defining stem cell dynamics and migration during wound healing in mouse skin epidermis. *Nat Commun*. 8: 14684.
3. Artus M et al (2010) Low back pain symptoms show a similar pattern of improvement following a wide range of primary care treatments: a systematic review of randomized clinical trials. *Rheumatology (Oxford)*. 49(12):2346-56.
4. Baumann BC et al (2018) Assessing the Validity of Clinician Advice That Patients Avoid Use of Topical Agents Before Daily Radiotherapy Treatments. *JAMA Oncology*, doi:10.1001/jamaoncol.2018.4292.

5. Belinchón I., Rivera R., Blanch C., Comellas M., Lizán L. (2016) Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: A systematic review of the literature. *Patient Preference Adherence*. 10:2357–2367. doi: 10.2147/PPA.S117006.

6. Blazquez R et al (2014) Immunomodulatory Potential of Human Adipose Mesenchymal Stem Cells Derived Exosomes on *in vitro* Stimulated T Cells. *Front Immunol*. 2014; 5: 556

7. Bowman A and Birch-Machin MA (2016) Age-Dependent Decrease of Mitochondrial Complex II Activity in Human Skin Fibroblasts. *J Invest Dermatology* 136: 912-919

8. Chen et al (2008) Paracrine Factors of Mesenchymal Stem Cells Recruit Macrophages and Endothelial Lineage Cells and Enhance Wound Healing. PLoS One. 3(4): e1886.

9. Chicharro D et al (2018) Combined plasma rich in growth factors and adipose-derived mesenchymal stem cells promotes the cutaneous wound healing in rabbits. *BMC Vet Res*. 14: 288.

10. Corstjens H, Dicanio D, Muizzuddin N, Neven A, Sparacio R, Declercq L, et al. (2008) Glycation ssociated skin autofluorescence and skin elasticity are related

- to chronological age and body mass index of healthy subjects. *Exp Gerontol.* 43:663–7. doi: 10.1016/j.exger.2008.01.012
11. Deng Y., Chang C., Lu Q. (2016) The inflammatory response in psoriasis: A comprehensive review. *Clin. Rev. Allergy Immunol.* 50:377–389. doi: 10.1007/s12016-016-8535-x.
12. Eckes B, Zweers MC, Zhang ZG, Hallinger R, Mauch C, Aumailley M, Krieg T (2006) Mechanical tension and integrin $\alpha 2 \beta 1$ regulate fibroblast functions. *J Invest Dermatol Symp Proc* 11: 66–72.
13. Ellingsen DM et al (2013) Placebo improves pleasure and pain through opposite modulation of sensory processing. *Proc Natl Acad Sci U S A.* 110(44): 17993–17998.
14. Eriksen JG, Kaalund I, Clemmensen O, Overgaard J, Pfeiffer P. (2017) Placebo-controlled Phase study II of vitamin K3 cream for the treatment of cetuximab-induced rash. **Support. Care Cancer** 25(7), 2179–2185.
15. Ernst O and Zor T (2010) Linearization of the bradford protein assay. *J Vis Exp.*(38). pii: 1918. doi: 10.3791/1918
16. Evans (2011) Fundamentals of clinical trial design. *J Exp Stroke Transl Med.* 3(1): 19–27.
17. Fuchs, E., and Green, H. (1978). The expression of keratin genes in epidermis

and cultured epidermal cells. Cell 15, 887–897.

18. Fukuoka H, Suga H. (2015) Hair regeneration treatment using adipose-derived stem cell conditioned medium: follow-up with trichograms. Eplasty. 15:e10.
19. Gerstein AD, Phillips TJ, Rogers GS, Gilchrest BA (1993) Wound healing and aging. Dermatol Clin 11: 749–757.
20. Giangreco A et al (2008) Epidermal stem cells are retained *in vivo* throughout skin aging. Aging Cell. 1; 7(2): 250–259.
21. Gosain A, DiPietro LA (2004) Aging and wound healing. World J Surg 28: 321–326.
22. Goldberg B and Sherr CJ (1973) Secretion and extracellular processing of procollagen by cultured human fibroblasts. Proc. Natl. Acad. Sci. USA, 70:361–365.
23. Hofheinz R-D, Lorenzen S, Trojan J *et al.* (2018) EVITA—a double-blind, vehicle-controlled, randomized Phase trial II of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Ann. Oncol.29(4), 1010–1015.
24. Hong J et al (2008) Difference gel electrophoresis analysis of Ras-transformed fibroblast cell-derived exosomes. Electrophoresis, <https://doi.org/10.1002/elps.200800015>
25. Hu L, Zhao J, Liu J, et al. (2013) Effects of adipose stem cell-conditioned

medium on the migration of vascular endothelial cells, fibroblasts and keratinocytes. *Exp Ther Med*. 5(3):701–706.

26. Huang H, Qiu W, Zhu M, Zhang Y, Cui WH, Xing W, Li XY, An TC, Chen MJ, Guo W, Xu X. (2016) Expressions of the key proteins of the protein kinase B/mammalian target of rapamycin signaling pathway in skin tissue and wound tissue of diabetic rats. *Zhonghua Shao Shang Za Zhi*. 2016 Oct 20;32(10):588-593. doi: 10.3760/cma.j.issn.1009-2587.2016.10.004.

27. Hur W and Yoon SK (2017) Molecular Pathogenesis of Radiation-Induced Cell Toxicity in Stem Cells. *Int J Mol Sci*. 18(12): 2749.

28. Kurd SK, Gelfand JM (2009) The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. *J Am Acad Dermatol*. 60:218–224. doi: 10.1016/j.jaad.2008.09.022.

29. Liu X et al (2018) Exosomes secreted by adipose-derived mesenchymal stem cells regulate type I collagen metabolism in fibroblasts from women with stress urinary incontinence. *Stem Cell Research & Therapy* 9:159

30. Lo Cicero A et al (2015) Exosomes released by keratinocytes modulate melanocyte pigmentation. *Nature Communications*, 6: 7506

31. Lundberg KC et al (2015) Proteomics of Skin Proteins in Psoriasis: From Discovery and Verification in a Mouse Model to Confirmation in Humans. *Molecular & Cellular Proteomics*, 14 (1) 109-119

32. Maguire G (2013) Stem cell therapy without the cells. *Commun Integr Biol.* 6(6):e26631.

33. Maguire G (2016) Therapeutics from Adult Stem Cells and the Hype Curve. *ACS Med Chem Lett.* 7(5):441-3.

34. Maguire G.. (2016b) Exosomes: Smart Nanospheres for Drug Delivery Naturally Produced by Stem Cells. In *Fabrication and Self-Assembly of Nanobiomaterials*; Elsevier: Amsterdam, 2016; pp 179–209.

35. Maguire G (2018) Stem Cell Released Molecules: A Paradigm Shift to Systems Therapeutics. Nova Scientific Publishes, New York.

36. Maguire G et al (2018) Protein circuits in wound healing. *Science, eletters*, 362(6417).

37. Maguire G et al (2019) Rescue of Degenerating Neurons and Cells by Stem Cell Released Molecules. *Physiological Reports*, In Press.

38. Maguire G (2019b) The Safe and Efficacious Use of Secretome From Fibroblasts

and Adipose-, But Not Bone Marrow-, Derived Mesenchymal Stem Cells For Skin Therapeutics. In Press.

39. Mahmood and Bowe (2014) Diet and Acne Update: Carbohydrates Emerge as the Main Culprit. *J Drugs Dermatol*. 13(4):428-435.

40. Mascré G, Dekoninck S, Drogat B, Youssef KK, Broheé S, Sotiropoulou PA, et al. (2012) Distinct contribution of stem and progenitor cells to epidermal maintenance. *Nature*. 489(7415):257–62. pmid:22940863

41. Mauch C, Hatamochi A, Scharffetter K, Krieg T (1988) Regulation of collagen synthesis in fibroblasts within a three-dimensional collagen gel. *Exp Cell Res* 178: 493–503

42. McDonald CJ et al (1983) How much of the placebo effect is really statistical regression? *Statistics in Medicine*, 2: 417-427

43. Miller RC et al. (2011) Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the north central Cancer treatment group N06C4. *Int J Radiat Oncol Biol Phys*. 79(5):1460–1466. doi: 10.1016/j.ijrobp.2010.01.031

44. Nestle FO, et al. (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. *Journal of Experimental Medicine*. 202:135–143. doi: 10.1084/jem.20050500.

- 1
2
3 45. O'Connell NE et al (2015) Interpreting Effectiveness Evidence in Pain: Short Tour
4
5 of Contemporary Issues. *Phys Ther.* 95:1087-1094
6
7
8 46. Owczarczyk-Saczonek A et al (2017) Stem Cells as Potential Candidates for
9
10 Psoriasis Cell-Replacement Therapy. *Int J Mol Sci.* 18(10): 2182.
11
12
13 47. Pardee AB (1974) A restriction point for control of normal animal cell proliferation.
14
15 *Proc Natl Acad Sci U S A.* 71(4):1286-90
16
17
18 48. Pearl J (2018) *The Book of Why. The New Science of Cause and Effect.* Basic
19
20 Books, New York, NY.
21
22
23 49. Quan T, He T, Kang S, et al. (2004) Solar ultraviolet irradiation reduces collagen
24
25 in photoaged human skin by blocking transforming growth factor-beta type II
26
27 receptor/Smad signaling. *Am J Pathol.* 165(3):741–751.
28
29
30 50. Quan T, Wang F, Shao Y, Rittié L, Xia W, Orringer JS, Voorhees JJ, Fisher GJ
31
32 (2013) Enhancing structural support of the dermal microenvironment activates
33
34 fibroblasts, endothelial cells, and keratinocytes in aged human skin in vivo. *J*
35
36 *Invest Dermatol* 133: 658–667.
37
38
39 51. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. (2004)
40
41 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk:
42
43 systematic review and meta-regression analysis. *Lancet.* 363(9418):1346-7.
44
45
46 52. Rheinwald, J.G., and Green, H. (1975). Serial cultivation of strains of human
47
48 epidermal keratinocytes: the formation of keratinizing colonies from single cells.
49
50 *Cell* 6, 331–343.
51
52
53 53. Rittié L, Berton A, Monboisse JC, Hornebeck W, Gillery P (1999) Decreased
54
55 contraction of glycated collagen lattices coincides with impaired matrix
56
57
58
59
60

- metalloproteinase production. *Biochem Biophys Res Commun* 264: 488–492.
54. Rittie L and Fisher GJ (2015) Natural and Sun-Induced Aging of Human Skin. *Cold Spring Harb Perspect Med.* 5(1): a015370.
55. Rivera-Gonzalez G et al (2016) PDGFA regulation of dermal adipocyte stem cells. *Cell Stem Cell*, 4:72. doi: 10.21037/sci.2017.08.03
56. Rodriguez-Menocal L et al (2012) Stimulation of Skin and Wound Fibroblast Migration by Mesenchymal Stem Cells Derived from Normal Donors and Chronic Wound Patients. *Stem Cells Translational Medicine*, 1:221–229
57. Rognoni E et al (2018) Fibroblast state switching orchestrates dermal maturation and wound healing. *Molecular Systems Biology* 14, e8174.
58. Sanmamed MF and Chen L (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. *Cell*, 175: 313-326
59. Santer M et al. (2012) Experiences of carers managing childhood eczema and their views on its treatment: a qualitative study. *Br J Gen Pract* 62:e261–e267. 10.3399/bjgp12X636083
60. Senn S (2011) Francis Galton and regression to the mean. *Focus*, Sept. 2011, 124-126.
61. Skirou AD et al (2017) 6-bromo-indirubin-3'-oxime (6BIO), a Glycogen synthase kinase-3 β inhibitor, activates cytoprotective cellular modules and suppresses cellular senescence-mediated biomolecular damage in human fibroblasts. *Sci Rep.* 7: 11713.

62. Smith J, Davidson E, Sams W, Clark R. (1962) Alterations in human dermal connective tissue with age and chronic sun damage. *J Invest Dermatol.* 39:347–350

62. Smith AN et al (2010) Mesenchymal stem cells induce dermal fibroblast responses to injury. *Exp Cell Res.* 316(1): 48–54.

63. Smith SD, Hong E, Fearn S, et al. (2010b) Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. *Australas J Dermatol* 51:168–74. 10.1111/j.1440-0960.2010.00636.x

64. Son WC, Yun JW, Kim BH. (2015) Adipose-derived mesenchymal stem cells reduce MMP-1 expression in UV-irradiated human dermal fibroblasts: therapeutic potential in skin wrinkling. *Biosci Biotechnol Biochem.* 79(6):919–925

65. Suh EJ et al (2012) A microRNA network regulates proliferative timing and extracellular matrix synthesis during cellular quiescence in fibroblasts. *Genome Biol.* 13(12): R121.

66. Swiecki M, Colonna M. (2010) Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. *Immunological Reviews.* 234:142–162. doi: 10.1111/j.0105-2896.2009.00881.x.

67. Taylor AP (2017) The Ever-Expanding T-Cell World: A Primer. *The Scientist*, Aug 7, 2017
68. Tononi G and Cirelli C (2014) Sleep and the Price of Plasticity: From Synaptic and Cellular Homeostasis to Memory Consolidation and Integration. *Neuron*. 81(1): 12–34.
69. Turlier V, Delalleau A, Casas C, Rouquier A, Bianchi P, Alvarez S, Josse G, Briant A, Dahan S, Saint-Martory C, et al (2013) Association between collagen production and mechanical stretching in dermal extracellular matrix: In vivo effect of cross-linked hyaluronic acid filler. A randomised, placebo-controlled study. *J Dermatol Sci* 69: 187–194.
70. Waibel JS, Wulkan AJ, Shumaker PR. (2013) Treatment of hypertrophic scars using laser and laser assisted corticosteroid delivery. 45(3):135–40.
71. Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ, Voorhees JJ (2007) In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. *Arch Dermatol* 143: 155–163
72. Wang L et al (2017) Exosomes secreted by human adipose mesenchymal stem cells promote scarless cutaneous repair by regulating extracellular matrix remodeling. *Scientific Reports* 7, Article number: 13321
73. Weidinger S and Novak N. (2016) Atopic dermatitis. *The Lancet* 387:1109–22. 10.1016/S0140-6736(15)00149-X

74. Williams G, Zentar MP, Gajendra S, Sonogo M, Doherty P, Lalli G. (2013) Transcriptional basis for the inhibition of neural stem cell proliferation and migration by the TGFβ-family member GDF11. *PLoS One*, 8:e78478.

75. Wohn, C. *et al.* (2013) Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 10723–10728, 10.1073/pnas.1307569110.

76. Yamazaki H *et al* (2018) Comparison of radiation dermatitis between hypofractionated and conventionally fractionated postoperative radiotherapy: objective, longitudinal assessment of skin color. *Sci Rep*. 2018; 8: 12306.

77. Zappasodi R *et al* (2018) Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. *Cancer Cell*. 33(4):581-598

Figure Captions

Figure 1. Before and after surgery using S2RM technology. After photo was one year following surgery.

Figure 2. Traumatic wounds to the arms and hands were more completely and faster healing using twice daily Recovery (S2RM) application. A. Initial traumatic wound to arm. B. After 21 days following initial traumatic wound, using Recovery (S2RM) application twice daily. C. In the same patient, in the same traumatic event, wounds were compared without the use of Recovery (S2RM) to those shown in A and B where

Recovery (S2RM) was used. Here showing the initial traumatic wound. D. Wound recovery 21 days following the initial traumatic wound were followed without the application of Recovery (S2RM). Wound healing with the use of Recovery (S2RM) shown in A and B was faster and more complete than that without the use of Recovery (S2RM) as shown in C and D.

Figure 3. Before and after chemical peel and radiation treatment. Chemical peel burn is shown in A. After photo (B) is 9th day of radiation treatment, and C. last day of treatment 21 days after initial treatment. S2RM technology topically applied twice daily.

Figure 4. Post Laser treatment using NeoGenesis Recovery. Patient is shown just after the procedure on the left, and 5 days postprocedure on the right.

Figure 5. Treatment of eczema with topical application of S2RM technology applied daily for two months. Patient has suffered with this rash for over 20 years.

Figure 6. Within subjects comparison of recovery from laser treatment with topical standard of care versus S2RM stem cell released molecules topical care. The subject was irradiated with a XYZ laser on both hands. The top photo shows recovery from the laser wound using the standard of care, XYZ cream. The lower photo shows recovery from the laser procedure using S2RM stem cell technology.

Figure 7. Before and after (Day 42) using topical application of Recovery on a patient with psoriasis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 8. Post Fluorouracil (5-FU) treatment in cancer patient. Left column is the patient before application of Recovery, and the pictures in the right column show the patient 24 hrs following the initial application of Recovery.

Figure 9. Post proton radiation treatment in cancer patient. Photos from top left to bottom right are at day 1, 7, 14, and 27 post radiation treatment, and beginning of Recovery (S2RM) topical application.

Figure 10. S2RM application during radiation treatment in cancer patients prevent radiation dermatitis and augments scarless healing of scalpel surgery. Patient had *bilateral mastectomy; lymph/aux node dissection; thyroidectomy, and then treated with chemo followed by radiation treatment. The photos, from top left to bottom right, were captured at weeks 1,2,3,4,5,13.*

Figure 11. Patient underwent chemo for breast cancer. One side effect was a rash that worsened with each treatment, leading to scabbing and bleeding over a 3 month period. Recovery applied twice a day for seven days significantly improved the look and feel of the skin. It also reduced the pain and irritation for the patient. From the patient: “No other product has helped like Recovery.” This patient was treated with a combination of Cyclophosphamide and Doxorubicin for four weeks.

Figure 12. Remediation of old scar that had resulted from Fraxel Laser treatment. Scar persisted as shown in the left photo for one year despite treatment from the patient’s dermatologist. Within 30 days using twice daily application of Recovery the scar became nearly invisible.

Figure 13. Anti-aging effects of topically applied S2RM. Picture on the left is the subject before treatment, and the picture on the right is 34 days after beginning treatment with Recovery.

Figure 14. Simple topical application of S2RM technology using NeoGenesis Recovery was administered twice daily. Within 7 weeks of treatment initiation, the acneic breakout as shown by redness, whiteheads, and blackheads was significantly reduced.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CrA
view Only



Figure 1

254x190mm (96 x 96 DPI)



Figure 2

254x190mm (96 x 96 DPI)



Figure 3

254x190mm (96 x 96 DPI)



Figure 4
254x190mm (96 x 96 DPI)



Figure 5

254x190mm (96 x 96 DPI)



Figure 6
254x190mm (96 x 96 DPI)



Figure 7

254x190mm (96 x 96 DPI)



Figure 8

254x190mm (96 x 96 DPI)



Figure 9

254x190mm (96 x 96 DPI)



Figure 10
254x190mm (96 x 96 DPI)



Figure 11

254x190mm (96 x 96 DPI)




Figure 12
254x190mm (96 x 96 DPI)



Figure 13

254x190mm (96 x 96 DPI)



Figure 14
254x190mm (96 x 96 DPI)